Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Two-Stage Citrate Anticoagulation Protocol Reduces Venous Clotting in Hemodialysis Trial

7 hours ago 12

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

In a single-center randomized crossover trial, a two-stage regional citrate anticoagulation protocol demonstrated a favorable but statistically nonsignificant trend toward improved effective anticoagulation compared to a simplified protocol during intermittent hemodialysis. Effective anticoagulation was achieved in 26 of 30 sessions using the two-stage protocol compared to 19 of 30 sessions using simplified anticoagulation, corresponding to success rates of 86.7 percent and 63.3 percent (P = 0.063). The investigation evaluated whether redistributing citrate downstream could resolve circuit clotting issues in adults with active bleeding or high bleeding risk.

Conventional regional citrate anticoagulation is established as effective for patients with high bleeding risk, yet it remains operationally complex in clinical practice. The simplified regional citrate anticoagulation approach uses calcium-containing dialysate combined with a pre-dialyzer citrate infusion. Nevertheless, the removal of citrate across the dialyzer membrane can leave the venous bubble trap insufficiently anticoagulated, creating a vulnerability in the circuit that investigators sought to address by comparing it against a two-stage method.

The evaluated alternative, designated two-stage regional citrate anticoagulation, redistributes part of the total citrate dose downstream from the dialyzer to protect vulnerable circuit components. The study protocol was conducted as a single-center, open-label, randomized crossover trial and registered with the Chinese Clinical Trial Registry under identifier ChiCTR2000034314 on September 28, 2020. The study cohort comprised 30 adult patients presenting with active bleeding or high bleeding risk, each assigned to complete two 4-hour intermittent hemodialysis sessions to assess both anticoagulation strategies.

The trial protocol defined effective anticoagulation as completing the planned 4-hour hemodialysis session with clotting grades below 3 in both the dialyzer and the venous bubble trap. All 30 participating patients successfully completed both treatment periods. While effective anticoagulation occurred in 86.7 percent of two-stage sessions versus 63.3 percent of simplified sessions, this primary comparison did not achieve formal statistical significance (P = 0.063).

Beyond the primary endpoint, the investigators evaluated secondary outcomes that included circuit survival, component-specific clotting grades, dialysis adequacy, biochemical changes, and adverse clinical events. Treatment session duration was significantly longer with the two-stage protocol, averaging 3.94 ± 0.21 hours compared to 3.68 ± 0.60 hours with the simplified protocol, reflecting a mean difference of 0.26 hours (95% CI, 0.03 to 0.48; P = 0.027). Furthermore, clotting within the venous bubble trap was significantly less severe under the two-stage protocol (P = 0.001), while dialyzer clotting severity and dialysis adequacy were comparable between the two interventions.

Biochemical evaluations focused on postdialysis systemic ionized calcium and within-session mineral changes. Postdialysis systemic ionized calcium measured 1.02 ± 0.11 mmol/L following the two-stage protocol and 1.08 ± 0.13 mmol/L following the simplified protocol, a difference that reached statistical significance (P = 0.031). However, the between-protocol difference in within-session ionized calcium change was not statistically significant (P = 0.054). Documented adverse events included five hypoglycemic episodes under each protocol and one hypotensive event under the simplified protocol, with no serious citrate-related events observed across all treatments.

In their research report published in BMC Nephrology, authors Shizhu Yuan, Yueming Liu, Qiudi Tu, Meiling Zhou, Yanqing Jia, and Xiadan Xiang concluded that two-stage regional citrate anticoagulation exhibited a favorable trend toward improved anticoagulation efficacy. Emphasizing that these single-center findings provide hypothesis-generating evidence and reflect a potentially meaningful signal, the researchers noted that larger multicenter randomized trials with adequate statistical power are warranted to confirm the comparative efficacy and safety of the two protocols.

Subject of Research: Two simplified regional citrate anticoagulation protocols in intermittent hemodialysis

Article Title: Efficacy and safety of two simplified regional citrate anticoagulation protocols in intermittent hemodialysis: a randomized crossover trial

Article References: Yuan, S., Liu, Y., Tu, Q., Zhou, M., Jia, Y., & Xiang, X. (2026). Efficacy and safety of two simplified regional citrate anticoagulation protocols in intermittent hemodialysis: a randomized crossover trial. BMC Nephrology. https://doi.org/10.1186/s12882-026-05508-6

Image Credits: AI Generated

DOI: 10.1186/s12882-026-05508-6

Keywords: regional citrate anticoagulation, intermittent hemodialysis, two-stage citrate anticoagulation, simplified regional citrate anticoagulation, venous bubble trap, dialyzer clotting, calcium-containing dialysate, systemic ionized calcium, dialysis adequacy, bleeding risk, randomized crossover trial, circuit survival, hypoglycemic events, hypotension, citrate infusion, BMC Nephrology

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway